

BMP signaling regulates satellite cell-dependent postnatal muscle growth

Amalia Stantzou^{1,2,3}, Elija Schirwis^{1,3,4}, Sandra Swist^{5,6}, Sonia Alonso-Martin^{3,7}, Ioanna Polydorou^{1,2}, Faouzi Zarrouki¹, Etienne Mouisel^{3,8}, Cyriaque Beley⁹, Anaïs Julien¹⁰, Fabien Le Grand³, Luis Garcia¹, Céline Colnot¹⁰, Carmen Birchmeier⁴, Thomas Braun⁵, Markus Schuelke², Frédéric Relaix^{3,7} and Helge Amthor^{1,11,*}

ABSTRACT

Postnatal growth of skeletal muscle largely depends on the expansion and differentiation of resident stem cells, the so-called satellite cells. Here, we demonstrate that postnatal satellite cells express components of the bone morphogenetic protein (BMP) signaling machinery. Overexpression of noggin in postnatal mice (to antagonize BMP ligands), satellite cell-specific knockout of *Alk3* (the gene encoding the BMP transmembrane receptor) or overexpression of inhibitory SMAD6 decreased satellite cell proliferation and accretion during myofiber growth, and ultimately retarded muscle growth. Moreover, reduced BMP signaling diminished the adult satellite cell pool. Abrogation of BMP signaling in satellite cell-derived primary myoblasts strongly diminished cell proliferation and upregulated the expression of cell cycle inhibitors *p21* and *p57*. In conclusion, these results show that BMP signaling defines postnatal muscle development by regulating satellite cell-dependent myofiber growth and the generation of the adult muscle stem cell pool.

KEY WORDS: BMP signaling, Postnatal muscle growth, Satellite cells, Muscle stem cells, Mouse

INTRODUCTION

The basic cellular units of skeletal muscle are myofibers, which are multinuclear syncytia capable of contraction. Myofibers, which are generated during prenatal development, continue to grow after birth (White et al., 2010). This postnatal growth requires a sufficiently large pool of muscle precursors, the so-called satellite cells, which reside between the basal lamina and the sarcolemma of muscle fibers (Mauro, 1961). During the first 3 weeks of postnatal mouse development, muscle fibers grow through the recruitment of

satellite cells (accretion), thereby enlarging the number of myonuclei, as well as expanding the cytoplasmic domain. Thereafter, muscle fibers grow mainly by expanding their cytoplasmic volume without further addition of myonuclei (White et al., 2010). Whereas postnatal satellite cells cycle to generate progenitors for fusion with the muscle fibers, they are quiescent in adult muscle and are only reactivated for the regeneration of damaged muscle fibers (Beilharz et al., 1992). The postnatal growth period is accompanied by a steady decline in the number of muscle satellite cells until 21 days after birth and remains stable thereafter throughout adulthood (White et al., 2010).

Little is known about the intercellular signaling systems that guide postnatal muscle growth and determine adult satellite cell number. We and others have previously described the crucial role of bone morphogenetic proteins (BMPs) during embryonic, fetal and adult muscle growth (Amthor et al., 1998, 1999, 2002; Hirsinger et al., 1997; Ono et al., 2011; Pourquie et al., 1996; Sartori et al., 2013; Wang et al., 2010). In parallel with other members of the TGF β family of signaling molecules, BMPs act on target cells via transmembrane serine/threonine kinase receptors. BMPs bind to type II and type I receptors, and form a ligand-receptor complex that permits the phosphorylation of the type I receptor via the constitutively active type II receptor (Nohe et al., 2004, 2002). The type I receptor in turn phosphorylates the BMP-responsive Smad1/5/8 proteins. Phosphorylated Smad1/5/8 proteins subsequently form complexes with co-Smad4 and translocate into the nucleus to regulate transcriptional activity of target genes such as DNA-binding protein inhibitors (*Ids*) (Miyazono and Miyazawa, 2002). Four isoforms of these proteins (*Id1-4*) block the binding of E proteins with the myogenic regulatory transcription factor MyoD and inhibit terminal differentiation (Jen et al., 1992). Interestingly, BMP signaling upregulates the inhibitory *Smad6* as part of a negative feedback loop. *Smad6* interferes with BMP signaling at the level of the receptor, as well as at the level of the complex formation between receptor-regulated Smad1 and the common mediator co-Smad4 (Goto et al., 2007).

A number of secreted proteins, such as noggin (Nog), can non-covalently bind BMPs, thereby impeding their receptor binding (Amthor et al., 2002; Krause et al., 2011). The BMP/Nog antagonism regulates satellite cell lineage progression. We have previously demonstrated *in vitro* that BMP signaling stimulated proliferation of activated adult satellite cells and inhibited myogenic differentiation, whereas abrogation of BMP signaling via addition of Nog, induced precocious differentiation (Ono et al., 2011). Interestingly, myotube formation is delayed in *Nog*-null mice, pointing to a requirement for Nog expression for proper muscle differentiation (Tylzanowski et al., 2006). Moreover, injection of Nog into regenerating muscle inhibited BMP signaling and reduced P-Smad1/5/8, Id1 and Id3 protein levels (Clever et al., 2010).

¹Versailles Saint-Quentin-en-Yvelines University, INSERM U1179, LIA BAHN CSM, Montigny-le-Bretonneux 78180, France. ²Department of Neuropediatrics and NeuroCure Clinical Research Center, Charité University-Medicine, Berlin 10117, Germany. ³Pierre et Marie Curie University, Paris Sorbonne, INSERM, UMRS974, CNRS FRE3617, Center for Research in Myology, Paris 75013, France.

⁴Developmental Biology/Signal Transduction Group, Max Delbrück Center for Molecular Medicine, Berlin 13092, Germany. ⁵Department of Cardiac Development and Remodeling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim 61231, Germany. ⁶Department of Cardiovascular Physiology, Ruhr University Bochum, D-44780 Bochum, Germany. ⁷INSERM, Paris Est University, IMRB U955-E10, Créteil 94010, France. ⁸Paul Sabatier University, Inserm UMR 1048, Toulouse 31432, France. ⁹SQY Therapeutics, Montigny-le-Bretonneux 78180, France.

¹⁰Paris Descartes-Sorbonne Paris Cité University, Inserm UMR1163, Imagine Institute, Paris 75015, France. ¹¹Pediatric Department, University Hospital Raymond Poincaré, Garches 92380, France.

*Author for correspondence (helge.amthor@uvsq.fr)

© S.A., 0000-0002-3254-0365; F.R., 0000-0003-1270-1472; H.A., 0000-0003-1008-719X

Based on our previous *in vitro* findings (Ono et al., 2011), we set out to determine the role of BMP signaling on satellite cells *in vivo*. We chose the early postnatal/juvenile growth phase of mouse limb muscles as our main experimental model because satellite cell activation, proliferation and differentiation, as well as fiber growth, can be much more easily observed when compared with regeneration models. We used three independent techniques to interfere with BMP signaling in satellite cells: (1) addition of Nog, which interferes at the ligand level; (2) abrogation of the BMP transmembrane receptor *Alk3*, which interferes at the receptor level; and (3) overexpression of *SMAD6*, which interferes with BMP signaling at the cell-autonomous level. We show that abrogation of BMP signaling severely inhibits satellite cell activity, myonuclear recruitment and the generation of the adult satellite cell pool.

RESULTS

BMP signaling is active in postnatal muscle satellite cells

We first asked whether the BMP signaling pathway is active during the postnatal growth phase of skeletal muscle. We found the presence of transcripts of genes encoding different BMP ligands, the BMP receptor *Alk3* (also known as *Bmpr1a*), the BMP target gene *Id1* (Miyazono and Miyazawa, 2002), as well as the BMP antagonists *Nog*, *Grem1*, *Fst* and *Chrd* (respectively encoding for Nog, gremlin 1, follistatin and chordin) in total RNA extracted from limb skeletal muscle of 3-, 14-, 21- and 28-day-old mice (Fig. S1A). Generally, the mRNA concentrations for BMP signaling components declined from postnatal to young adult stages.

In order to identify whether satellite cells respond to BMP signaling, we monitored the nuclear accumulation of BMP-induced Smad1/5 proteins in Pax7-positive nuclei using double immunohistochemistry. We discovered P-Smad1/5-positive and

-negative satellite cells in postnatal, juvenile and young adult muscle (from 3-, 14-, 21- and 28-day-old mice) (Fig. 1). We also found P-Smad1/5-positive nuclei that were negative for Pax7, which mainly were myonuclei within myofibers, as judged from their position.

We next examined the time frame and dynamics of the response of satellite cells to BMPs. For this, satellite cells were isolated from 6- to 8-week-old mice by magnetic-activated cell sorting (MACS) and expanded in culture, which maintained Pax7 expression in nearly 100% of cells in all the described conditions. Cells were then submitted to a serum-free culture condition supplemented with soluble Alk3 receptor for 6 h, thereby removing residual BMP ligands otherwise likely present in the culture medium. Thereafter, culture medium was replaced with serum-free medium containing 100 ng/ml of BMP4 for 1 h, which increased nuclear levels of phosphorylated Smad1/5 protein in the cells (Fig. S1B,C), clearly indicating that they respond to BMP signaling. Additionally, by performing a time course study, we found that *Id1* mRNA copy numbers peaked 1 h after BMP4 exposure and slowly declined thereafter (Fig. S1D). Interestingly, in control cultures, *Id1* expression increased slowly following medium change from Alk3 pre-treatment to vehicle supplemented control medium (not containing Alk3), suggesting that cells synthesize BMPs and therefore respond to BMP signaling in an autocrine/paracrine fashion. This hypothesis was further supported by the finding that *Id1* mRNA copy numbers in serum-deprived control cells could be further halved through addition of sAlk3, which sequestered the satellite cell-derived BMPs.

Having found that satellite cells activate the BMP signaling cascade, we next studied the expression of BMP signaling components in FACS-isolated muscle satellite cells from 3-, 14-,




Fig. 1. BMP signaling activity in satellite cells during postnatal muscle growth. Sample images of immunohistochemistry to monitor phosphorylated Smad1/5 (p-Smad1/5) expression (red) in Pax7-expressing satellite cells (green). Muscle sections were obtained from the tibialis anterior (TA) muscle of postnatal wild-type mice at P3, P14, P21 and P28 (panels from top to bottom). DAPI (blue) was used as a nuclear stain. All three channels (green, red and blue) were merged together with a differential interference contrast image (DIC), in which the individual fibers can be visualized. Cells that co-express p-Smad1/5 and Pax7 are highlighted with arrows. Scale bar: 50 μ m.

21- and 28-day-old mice. We found that satellite cells expressed transcripts of all BMP signaling components, as demonstrated above for whole-muscle extracts with the exception of only *Bmp14* (Fig. 2). Interestingly, mRNA expression levels were generally more than 10 times higher in satellite cells than in total muscle extracts (Fig. S1A). In total muscle extracts, the decline of satellite cell-specific gene expression signatures with muscle maturation towards day P21 can well be explained by a dilution effect due to the overall reduction of satellite cell number by 65% between days P6 and P21 (White et al., 2010). Expression levels of several genes encoding BMP signaling components in satellite cells, such as *Alk3*, *Id1* and *Nog*, transiently decreased at P14, whereas expression of others decreased from postnatal to adult stages or remained steady (Fig. 2). Among the different analyzed BMP ligands, *Bmp6* was most strongly expressed and expression peaked in adult satellite cells. These results suggest that BMP signaling plays a role during satellite cell-dependent postnatal muscle growth; however, there is no general rule in their expression dynamics during muscle maturation.

The BMP antagonist Nog retards postnatal satellite cell-dependent muscle growth

We next interrupted the BMP signaling cascade during postnatal muscle growth *in vivo* and ectopically overexpressed the BMP antagonist Nog by transfecting the whole muscle using an AAV-expressing vector. Tibialis anterior (TA) and triceps brachii (TB) muscles were transfected at P3 with an AAV-*Nog*, which resulted in high transgene expression (Fig. S2A). We have previously shown that AAV strongly transfects differentiated muscle fibers. However, as Nog is a secreted protein it would accumulate in the extracellular space. Nog overexpression significantly retarded muscle growth when compared with saline injected controls, which could be verified by anatomical analysis of skeletal muscle at 4 weeks of age (Fig. 3A). The muscle weight of *Nog*-treated muscles was considerably smaller than the weight of control limbs (Fig. 3B). Indeed, TB, TA and EDL (extensor digitorum longus) muscle

weights were reduced by 15%, 21% and 23%, respectively. Morphometric analysis of single fibers or of transverse sections from TA muscles revealed a strong shift of myofiber diameters towards smaller fiber sizes (Fig. 3C and Fig. S2B,E), whereas fiber length remained unchanged (Fig. S2C), which is evidence for postnatal fiber growth retardation. Postnatal skeletal muscle enlarges via continuous recruitment of satellite cells into the growing myofiber syncytium. Hence, the total number of myonuclei in one fiber reflects the cumulative history of previous satellite cell activity. In order to understand the cellular mechanism that results in *Nog*-induced growth retardation, we determined the total number of myonuclei on isolated muscle fibers from TA muscles prior to and after *Nog* overexpression. Prior to *Nog* transfection at day P3, muscle fibers contained 74 ± 2 myonuclei, which increased in control muscles to 419 ± 11 myonuclei, whereas *Nog*-treated myofibers increased the number of their myonuclei to only 244 ± 5 (mean \pm s.e.m.) (Fig. 3D and Fig. S2D). Thus, whereas the number of myonuclei increased by 5.7-fold between days P3 and P28 in controls, the presence of *Nog* reduced the increase to 3.3-fold, indicating that satellite cell function during postnatal myofiber growth might be impaired.

The BMP antagonist Nog decreases postnatal satellite cell activity

We next studied the effect of *Nog* on satellite cell proliferation during the postnatal growth phase. We treated mice at P3 with AAV-*Nog*, administered BrdU at P14 for 3 consecutive days and analyzed muscles at P17. The state of the muscle precursor cells was subsequently determined using anti-Pax7 and anti-BrdU immunostaining: Pax7⁺/BrdU⁺ marking proliferating satellite cells, Pax7⁺/BrdU⁻ marking quiescent satellite cells and Pax7⁻/BrdU⁺ with subsarcolemmal position marking former satellite cells that had divided and differentiated to become mitotically inactive once recruited into the myofiber (Fig. 4A). Interestingly, we found that the total number of Pax7⁺ cells was reduced after *Nog*-mediated




Fig. 2. Expression dynamics of BMP signaling pathway components in satellite cells during postnatal muscle growth. The relative mRNA copy numbers per 10^3 *Gapdh* mRNA copies of different BMP ligands (*Bmp2*, *Bmp4*, *Bmp5*, *Bmp6*, *Bmp7*, *Bmp13* and *Bmp14*), BMP receptor type I *Alk3*, BMP target gene *Id1*, BMP antagonists *Nog* (encoding Noggin), *Grem1* (encoding gremlin), *Fst* (encoding follistatin) and *Chrd* (encoding chordin) in satellite cells that were isolated by FACS from skeletal muscles of wild-type mice ($n=3$ biological and technical replicates) at P3, P14, P21 and P28. Data are mean \pm s.e.m.




Fig. 3. Consequences of Nog-mediated abrogation of BMP signaling for postnatal muscle growth. Triceps brachii (TB) muscle and the anterior compartment of the lower hindlimb were transduced with AAV-Nog at P3. Muscles were analyzed at 4 weeks of age. (A) Dorsal view of the forelimb shows significant muscle hypotrophy (arrowheads) of the AAV-Nog-treated TB muscle (right) when compared with the control saline-injected contralateral side (left). Sample images of $n=4$ injected mice. Scale bar: 1 cm. (B) Dot plots depict muscle wet weight of TB, TA and EDL muscles. Horizontal lines represent the median. (C) Histogram of the fiber diameters of 4-week-old TA muscle, analyzed on mid-belly muscle sections following immunostaining against laminin. Dashed lines represent the fitted normal distribution. (D) The number of myonuclei per single fiber of the TA muscle at P3 ($n=50$ fibers from 3 mice) and at P28 following AAV-Nog ($n=120$ fibers from 3 mice) or saline ($n=68$ fibers from 3 mice) injections at P3. Data are depicted as Whiskers-Tukey box plots. Boxes indicate the interquartile range (IQR), the horizontal line indicates the median, whiskers indicate $[1.5 \times \text{IQR}]$ and dots indicate the outliers.

abrogation of BMP signaling (Fig. 4B). Moreover, all three Pax7⁺/BrdU⁺, Pax7⁺/BrdU⁻ and Pax7⁻/BrdU⁺ cell populations were reduced after AAV-Nog treatment (Fig. 4B). Decreased satellite cell proliferation was thus the main cellular mechanism that caused reduced myonuclear recruitment and reduced postnatal muscle growth. Indeed, the precocious differentiation of satellite cells would be unlikely, as the number of newly formed myonuclei was reduced. Moreover, the reduction of the Pax7⁺/BrdU⁻ population suggested a decrease of satellite cell self-renewal and thus a decline of the satellite cell pool in states of abrogated BMP signaling.

At about 21 days of age, the final satellite cell number is established and does not further increase towards adulthood (White et al., 2010). We therefore wanted to investigate the consequence of this decreased satellite cell proliferation during the postnatal stages for the generation of the adult muscle stem cell pool. Remarkably, treatment with Nog at day P3 decreased the reservoir of satellite cells

at 4 weeks of age to about half the size of controls when counting Pax7⁺ and cadherin⁺ cells (Fig. 4C,D and Fig. S2E). In summary, these findings demonstrate that adult muscle stem cells are generated during the postnatal growth phase under the control of BMP signaling.

Conditional Alk3 knockout results in reduced postnatal muscle growth and a reduced satellite cell reservoir

In order to evaluate the role of BMP signaling in activated satellite cells during postnatal muscle growth more specifically, we tested the consequence of cell-autonomous abrogation of the BMP signaling pathway by ablating *Alk3*, the BMP type I receptor, exclusively in postnatal Pax7-expressing satellite cells. This aim was achieved by generating Pax7^{CreERT2/+};Alk3^{lox/lox} mice and inducing the *Alk3* knockout by administering tamoxifen at postnatal days P7 and P9. We analyzed the effect of *Alk3* knockout on muscle growth at 4 weeks of age in comparison with genetic controls (tamoxifen injected Alk3^{lox/lox} mice). Tamoxifen treatment of Pax7^{CreERT2/+};Alk3^{lox/lox} pups resulted, just like Nog treatment, in muscle fiber hypotrophy. Indeed, morphometric fiber size analysis of transverse cross-sections from TA muscles revealed a shift towards smaller fiber sizes (Fig. 5A,B). Similar to the Nog treatment, isolated EDL myofibers from tamoxifen-treated 4-week-old Pax7^{CreERT2/+};Alk3^{lox/lox} mice contained significantly fewer myonuclei than their respective controls (Fig. 5C). Furthermore, the number of Pax7⁺ satellite cells was also decreased in tamoxifen-treated Pax7^{CreERT2/+};Alk3^{lox/lox} mice when compared with controls (Fig. 5D).

Overexpression of SMAD6 inhibits satellite cell-dependent postnatal muscle growth and the generation of the adult satellite cell pool

We additionally tested a different means for cell-autonomous abrogation of BMP signaling during postnatal muscle growth via overexpression of *SMAD6*, an inhibitory Smad of the intracellular BMP signaling cascade, specifically in Pax7-expressing satellite cells. Such time- and lineage-specific expression of *SMAD6* was achieved by crossing Pax7^{CreERT2/+} mice with Rosa26^{Lox-Stop-Lox-huSMAD6-IRES-EGFP} (*RS6*) mice and subsequent activation of the transgene by tamoxifen through removal of a stop codon. *SMAD6* mRNA expression, taken as evidence for successful Cre-induced recombination (Fig. S2F), was found only in satellite cell-derived myoblasts from tamoxifen-treated Pax7^{CreERT2/+};RS6^{+/-} mice, but not from control mice. We administered tamoxifen to Pax7^{CreERT2/+};RS6^{+/-} mice at P7 and P9, and analyzed the effect on muscle growth at 4 weeks of age in comparison with genetic controls (tamoxifen-treated RS6^{+/-} mice), thus using the same experimental protocol as for the *Alk3* knockout. Tamoxifen treatment of Pax7^{CreERT2/+};RS6^{+/-} pups resulted in muscle fiber hypotrophy, similar to Nog treatment and *Alk3* knockout. Indeed, morphometric fiber size analysis of transverse cross-sections from TA muscles revealed a shift towards smaller fiber sizes in tamoxifen-treated Pax7^{CreERT2/+};RS6^{+/-} mice when compared with controls, indicating that the decrease of muscle growth results from a failure to increase the myofiber size (Fig. 6A, B). Importantly, this failure of muscle fiber growth was not compensated for during later development. Indeed, myofibers were still smaller in 2-month-old tamoxifen-treated Pax7^{CreERT2/+};RS6^{+/-} mice when compared with controls (Fig. S2G-I). Moreover, isolated EDL myofibers from tamoxifen-treated, 4-week-old Pax7^{CreERT2/+};RS6^{+/-} mice contained fewer myonuclei than their respective controls (Fig. 6C), whereas the myonuclear domain of the




Fig. 4. Effects of Nog-mediated abrogation of BMP signaling on postnatal satellite cell activity. The anterior compartment of the lower hindlimb was transduced with AAV-Nog at P3. At P14, the mice were treated for 3 consecutive days with subcutaneous injections of BrdU and were sacrificed at P17. (A) Fluorescence images of a mid-belly transverse section of a TA muscle following immunostaining against Pax7 in red (arrows), against BrdU (green) and against laminin (white); nuclei were stained with DAPI (blue). Pax7⁺/BrdU⁺ cells are indicated with white arrows. Pax7⁺/BrdU⁻ satellite cells and Pax7⁻/BrdU⁺ sublaminal myonuclei are, respectively, indicated with red and green arrows. Scale bar: 20 μ m. (B) The diagrams depict the number of Pax7⁺, Pax7⁺BrdU⁻ and Pax7⁺BrdU⁺ satellite cells, as well as the number of newly recruited Pax7⁺BrdU⁺ myonuclei per 100 myofibers from the TA muscle. $n=4$ biological replicates for each condition. (C,D) The anterior compartment of the lower hindlimb was transduced with AAV-Nog at P3. Muscles were analyzed at 4 weeks of age. The diagram depicts the number of Pax7⁺ (C) and of m-Cadherin⁺ (D) satellite cells per 100 myofibers quantified from whole TA muscle sections ($n=3$ or 4 for saline-injected control; $n=3$ for AAV-Nog-injected muscle). Horizontal lines represent the median and dots represent individual data points.

fibers remained unchanged (Fig. 6D). These results suggest decreased satellite cell activity during the postnatal muscle growth phase in satellite cells that lack BMP signaling. Indeed, the number of Pax7⁺ satellite cells, if quantified on both muscle cross-sections or isolated fibers, was decreased in tamoxifen-treated Pax7^{CreERT2/+}; RS6^{+/-} mice when compared with controls (Fig. 6E,F). Finally, the satellite cell pool remained decreased by 75% when 8-week-old TA muscles from tamoxifen-treated Pax7^{CreERT2/+}; RS6^{+/-} mice were compared with control muscles (Fig. S2J). This can be taken as further evidence that adult satellite cells are generated during the postnatal growth phase under the control of BMP signaling.

Expression of SMAD6 in myonuclei does not alter satellite cell and myonuclear number

The aforementioned experiments failed to provide unequivocal evidence of whether the SMAD6-mediated cell-autonomous inhibition of BMP signaling was the sole cause for the observed decrease in the numbers of satellite cells and myonuclei. As an alternative explanation, the inclusion of SMAD6-overexpressing myonuclei may indirectly influence satellite cell activity. Hence, we generated HSA-Cre⁺; RS6^{+/-} mice to overexpress SMAD6 exclusively in terminally differentiated myofibers. Muscles from these mice expressed SMAD6 as well as GFP, suggesting the

effective recombination of the transgene (Fig. S3A,B). Of note, GFP could be detected only on western blot and not using fluorescence analysis of dissected muscles *in toto* or of sectioned muscle (data not shown). Histological analysis of cross-sections of TA muscles from 4- and 8-week-old HSA-Cre⁺; RS6^{+/-} mice revealed a normal tissue architecture (Fig. S3C). Importantly, the number of Pax7⁺ satellite cells did not change in 4- and 8-week-old HSA-Cre⁺; RS6^{+/-} mice when compared with controls (Fig. S3D,E). Taken together, these experiments ruled out an indirect effect of SMAD6-overexpressing myonuclei on satellite cells and therefore confirm that BMP signaling acts in a cell-autonomous manner in satellite cells.

BMP signaling is required for myoblast activation and proliferation

We next used *in vitro* cell culture to further explore the role of BMP signaling on satellite cell-derived muscle precursor cells. Cultures of FACS-sorted satellite cells from adult forelimb and hindlimb Pax7^{CreERT2/+}; RS6^{+/-} muscles were treated either with 1 μ M hydroxytamoxifen (4-OHT) to evaluate the cell-autonomous effect of SMAD6 upregulation or with 50 ng/ μ l recombinant Nog to antagonize BMP ligands present in the culture medium (Fig. S4A). The 4-OHT-treated cells strongly expressed SMAD6, but not the cells from untreated control cultures (Fig. 7A). Furthermore, 4-




Fig. 5. Consequences of *Alk3* knockout in satellite cells on postnatal muscle growth. Mice were injected with tamoxifen (TXF) at P7 and P9, and sacrificed at the age of 1 month. (A,B) Quantification of the diameter of TA muscle fibers [depicted as Whiskers-Tukey box plots (A) and as a histogram (B)] of mid-belly muscle sections following immunostaining against laminin, from control tamoxifen-treated *Alk3^{flox/flox}* mice ($n=4$, gray) compared with tamoxifen-treated *Pax7^{CreERT2/+};Alk3^{flox/flox}* mice ($n=4$, white). (C) The Whiskers-Tukey box plots depict the number of myonuclei per isolated muscle fiber from EDL muscles from control tamoxifen-treated *Alk3^{flox/flox}* mice ($n=49$ fibers from 3 mice) compared with tamoxifen-treated *Pax7^{CreERT2/+};Alk3^{flox/flox}* mice ($n=77$ fibers from 3 mice). Boxes indicate the interquartile range (IQR), the horizontal line indicates the median, whiskers indicate [$1.5 \times$ IQR] and dots indicate the outliers. (D) The dot plot (median indicated by the horizontal line) depicts the number of Pax7⁺ satellite cells per 100 muscle fibers from TA muscles from control tamoxifen-treated *Alk3^{flox/flox}* mice ($n=5$, black dots) compared with tamoxifen-treated *Pax7^{CreERT2/+};Alk3^{flox/flox}* mice ($n=6$, white dots).

OHT and Nog downregulated the BMP target gene *Id1* (Fig. 7B). These results demonstrate the efficacy of the 4-OHT-induced recombination in *Pax7^{CreERT2/+};RS6^{+/-}* satellite cells and the value of Nog as a positive control for abrogation of BMP signaling.

We then assessed cell proliferation by monitoring clonal cell expansion after seeding cells at low density. After 5 days in culture, cells expressed MyoD (Fig. S4B) and lost expression of Pax7 (data not shown), which highlights the transition from satellite cells to committed myoblasts. Both treatment schemes with 4-OHT or with Nog reduced the number of satellite cell-derived myoblast progenitors below 50% of the control values (Fig. 7C). In a control experiment, 4-OHT revealed some inhibiting effect (the number of cells per colony was reduced by 14%) on cell proliferation on its own when treating FACS-isolated *Pax7^{CreERT2/+}* cells. However, this effect was less pronounced than the severe inhibition by Nog or by 4-OHT (the number of cells per colony was reduced by 58% for both treatments) on *Pax7^{CreERT2/+};RS6^{+/-}*-derived cells (Fig. 7C).

The reduction of cell numbers could not be accounted for by induction of apoptosis because none of the cells under these culture conditions expressed the apoptosis marker cleaved-caspase 3 (data not shown). Furthermore, we found similar proportions of cells expressing myogenin (MyoG) and myosin heavy chain (MHC) in

Pax7^{CreERT2/+};RS6^{+/-}-derived cultures treated with 4-OHT and Nog if compared with control cultures (Fig. 7D,E and Fig. S4B-D). This confirmed that the inhibition of BMP signaling does not affect cell lineage progression. Finally, we observed that the number of proliferating Ki67⁺ cells was decreased by 53% upon treatment with 4-OHT and by 45% with Nog (Fig. 7F and Fig. S4B,E). The decreased proliferation was associated with an increase in transcript levels for the cell cycle inhibitors p57 and p21, suggesting a cell cycle arrest as the likely molecular mechanism following abrogation of BMP signaling (Fig. 7G,H).

DISCUSSION

The present study has provided several important new insights about BMP signaling and its contribution to the regulation of satellite cell-dependent muscle growth in postnatal skeletal muscle. We show that postnatal satellite cells express *in vitro* as well as *in vivo* components of the BMP signaling pathway and respond to BMP signaling. These findings are reminiscent of previous observations on the role of BMP during embryonic and fetal chicken myoblast development and during adult murine satellite cell regulation (Amthor et al., 1998, 1999, 2002; Ono et al., 2011; Wang et al., 2010). We thus conclude that BMP signaling is an important regulator of muscle stem cell activity during all stages of muscle development.

We used AVV-vectors encoding Nog, an efficient antagonist of BMP2, BMP4, BMP5, BMP6, BMP7, BMP13 and BMP14 (all found to be expressed by satellite cells, with the exception of BMP14), as a means to abrogate BMP signaling (Krause et al., 2011). AAV highly transfects muscle fibers following intramuscular injection. Our working hypothesis was that Nog would mainly be synthesized and secreted from muscle fibers, thereby changing the signaling environment, including that of satellite cells by antagonizing locally present BMPs. We do not know whether AAV-Nog also transduced satellite cells. However, as the transgene remains episomal, it does not replicate during cell division and would be rapidly diluted among the muscle cell progenitors. We show that Nog-mediated BMP blockade decreased satellite cell proliferation, which well explains decreased myonuclear accretion during postnatal myofiber growth. However, our *in vivo* experiments using AAV-mediated Nog overexpression could not exclude the possibility of secondary effects on satellite cells, i.e. a change of signaling of the myofiber back to the satellite cells.

We thus used three different inducible Cre-lox systems to either ablate the expression of BMP receptor *Alk3* or to overexpress the BMP intracellular inhibitor *SMAD6* in either satellite cells or differentiated muscle fibers. Both means of cell-autonomous inhibition of BMP signaling (*Alk3* knockout or *SMAD6* overexpression) targeted to satellite cells resulted in smaller fibers containing fewer myonuclei and in reduced satellite cell number. We know little about the satellite cell progeny in our loss-of-function models. Our BrdU experiments suggest that satellite cells do not precociously differentiate and that they decline in number because of diminished proliferation. However, direct proof remains missing as the IRES-EGFP cassette of the recombined *Smad6* locus in *Pax7^{CreERT2/+};RS6^{+/-}* satellite cells was too weakly expressed to allow cell fate tracking. Thus, we cannot exclude other cellular mechanism such as apoptosis.

To address this issue further, we tested loss-of-function strategies *in vitro*. We confirmed diminished proliferation as being responsible for the insufficient progenitor generation. We did not find evidence, either *in vivo* or *in vitro*, of precocious differentiation of myogenic precursors after inhibition of the BMP pathway, which




Fig. 6. Consequences of SMAD6-mediated abrogation of BMP signaling in neonatal satellite cells on juvenile muscle growth. Mice were injected with tamoxifen (TXF) at P7 and P9, and sacrificed at the age of 1 month. (A,B) Quantification of the diameter of TA muscle fibers [depicted as Whiskers-Tukey box plots (A) and as a histogram (B)] of mid-belly muscle sections following immunostaining against laminin, from control tamoxifen-treated $RS6^{+/-}$ mice ($n=5$, gray) compared with tamoxifen-treated $Pax7^{CreERT2+};RS6^{+/-}$ mice ($n=4$, white). (C) The Whiskers-Tukey box plots depict the number of myonuclei per isolated muscle fiber from EDL muscles from control tamoxifen-treated $RS6^{+/-}$ mice ($n=51$ isolated fibers from 3 mice) compared with tamoxifen-treated $Pax7^{CreERT2+};RS6^{+/-}$ mice ($n=66$ isolated fibers from 4 mice). Boxes indicate the interquartile range (IQR), the horizontal line indicates the median, whiskers indicate $[1.5 \times IQR]$ and dots indicate the outliers. (D) The Whiskers-Tukey box plots depict the myonuclear domain analyzed on segments of isolated single fibers from control tamoxifen-treated $RS6^{+/-}$ mice ($n=98$ segments from 33 fibers) compared with tamoxifen-treated $Pax7^{CreERT2+};RS6^{+/-}$ mice ($n=182$ segments from 61 fibers). (E) The Whiskers-Tukey box plots depict the number of Pax7⁺ satellite cells per isolated muscle fiber from EDL muscles from control tamoxifen-treated $RS6^{+/-}$ mice ($n=51$ fibers from 3 mice) compared with tamoxifen-treated $Pax7^{CreERT2+};RS6^{+/-}$ mice ($n=73$ fibers from 4 mice). Boxes indicate the interquartile range (IQR), the horizontal line indicates the median, whiskers indicate $[1.5 \times IQR]$ and dots indicate the outliers. (F) The dot plot (median indicated by the horizontal line) depicts the number of Pax7⁺ satellite cells per 100 muscle fibers from TA muscles from control tamoxifen-treated $RS6^{+/-}$ mice ($n=6$, black dots) compared with tamoxifen-treated $Pax7^{CreERT2+};RS6^{+/-}$ mice ($n=8$, white dots).

stands in contrast to previous findings obtained from satellite cell cultures (Ono et al., 2011). We can only speculate about the reasons underlying such discrepancy. Possibly, the effect of Nog as well as of SMAD6 on the BMP target gene *Id1* in our study was too small to alter MyoD transcriptional activity and myogenic lineage progression. Of note, our study lacks experimental proof of whether BMP signaling worked via *Id1* to impinge on *MyoD* (*Myod1*) or on other targets. Moreover, previous work demonstrated unchanged satellite cell number in uninjured muscles following *Id* knockout (Clever et al., 2010). Thus, our finding that BMP signaling alters *Id1* expression was useful to demonstrate that BMP signaling was active in cells; however, it offered no explanation of the downstream molecular mechanism. Recent work demonstrated that myogenic proliferation and differentiation can be decoupled (Zalc et al., 2014). In agreement, we found here, following Smad6-induced abrogation of BMP signaling, increased expression of cell cycle inhibitors, notably of *p57* (*Cdkn1c*), which is known to increase stem cell quiescence in conjunction with a decreased proliferation rate (Matsumoto et al., 2011); however, myogenic progression towards myogenin and MHC expression was not altered. This offers a molecular mechanism for the function of BMPs on muscle stem cells, which remains to be explored in detail.

Interestingly, BMP signaling could modulate other signaling cascades, as recently demonstrated for Notch signaling, which becomes activated by BMP-induced Smad1/5 binding to the promoter of the Notch target gene *HES1* in colorectal cancer cells (Irshad et al., 2017). Such BMP-Notch signaling crosstalk, being

independent of *Id1*, could contribute to our observed phenotypes as Notch signaling is a crucial regulator of satellite cell function (Fukada et al., 2011). The dependence of satellite cells on additional signaling systems could well explain why our loss-of-function strategies did not completely abolish satellite cell activity and myofiber growth.

We show that cell-autonomous abrogation of BMP signaling targeted to satellite cells slowed but did not stop accretion of myonuclei. Resulting myofibers, therefore, consist of a mosaic of non-recombined and recombined myonuclei, once recombined satellite cells fuse into the syncytium. This, on the one hand, could signal back on the satellite cells. On the other hand, it could itself retard myofiber growth. Importantly, targeted overexpression of SMAD6 to differentiated muscle (*HSA-Cre⁺;RS6^{+/-}* mice) did not affect the number of myonuclei and satellite cells per fiber, thereby providing clear evidence for a direct effect of BMP signaling in satellite cells *in vivo*. Moreover, the myonuclear domain remained unchanged in muscle fibers from $Pax7^{CreERT2+};RS6^{+/-}$ mice, suggesting that the cytoplasmic volume per nucleus increased normally during the postnatal growth phase (White et al., 2010). This result stands in contrast to our previous work, which showed, in adult muscle, that decreased BMP signaling causes myofiber atrophy (Sartori et al., 2013).

Whereas we here show smaller satellite cell numbers in $Pax7^{CreERT2+};Alk3^{flox/flox}$ mice, the number remained unchanged in $Myf5^{Cre};Alk3^{flox/flox}$ mice (Huang et al., 2014). This implies that other BMP receptors or signaling pathways other than BMP may




Fig. 7. Quantitative analysis following abrogation of BMP signaling in cultured Pax7^{CreERT2/+};RS6^{+/-} satellite cell-derived primary myoblasts. Experimental protocol: at day 0, satellite cells from Pax7^{CreERT2/+} or Pax7^{CreERT2/+};RS6^{+/-} adult mice were isolated using FACS and cultured in proliferation media; from days 2-4, cells remained either untreated (control), or were treated with 1 μ M hydroxytamoxifen (4-OHT) or with 50 ng/ml of recombinant mouse Nog protein; at day 5, cells were either fixed for immunocytochemistry or collected for RNA extraction. (A,B) The dot plots (median indicated by the horizontal line) depict the relative mRNA copy numbers per 10³ Gapdh mRNA of human SMAD6 (A) or of the BMP target gene Id1 (B) from cultured satellite cells isolated from Pax7^{CreERT2/+};RS6^{+/-} mice. (C) Cells were cultured at low density for a proliferation assay for the comparison of non-treated versus treated satellite cells isolated by FACS from skeletal muscles of Pax7^{CreERT2/+} and Pax7^{CreERT2/+};RS6^{+/-} mice. The number of cells per colony was counted from at least three wells per condition and per mouse were quantified. Data are shown as Whiskers-Tukey box plots. All *P* values were calculated using a *t*-test. (D-F) Following cultures of satellite cells from Pax7^{CreERT2/+};RS6^{+/-} mice, the number of positive cells is given as a percentage of the total number of stained cells per colony following immunostaining against (D) myogenin (MyoG), (E) myosin heavy chain (MHC) and (F) Ki67. The quantification was performed on 13 to 20 colonies per culture ($n=3$ cultures, each derived from cells isolated from one mouse, total of $n=3$ mice). Data are shown as Whiskers-Tukey box plots. All *P* values were calculated using a *t*-test. In C-F, boxes indicate the interquartile range (IQR), the horizontal line indicates the median, whiskers indicate $[1.5 \times \text{IQR}]$ and dots indicate the outliers. (G,H) Dot plots (median indicated by the horizontal line) depict the relative mRNA copy numbers per 10³ Gapdh mRNA of (G) p21 and (H) p57 from FACS-isolated and cultured satellite cells from Pax7^{CreERT2/+};RS6^{+/-} mice. Cells remained either untreated (control, $n=4$) or were treated with 1 μ M 4-OHT ($n=3$) or 50 ng/ml of recombinant mouse Nog protein ($n=3$).

compensate for the deficit in Alk3 in satellite cells. This would be in line with our findings, as Alk3 loss of function in Pax7^{CreERT2/+}; Alk3^{lox/lox} mice resulted in a rather modest effect.

It is now common knowledge that adult muscle satellite cells are of somite origin (Relaix and Marcelle, 2009), but how the expansion of the satellite cell pool is controlled and which factors determine the final number of quiescent satellite cells in the adult stage was unknown. Here, we show that BMP signaling controls the generation of adult satellite cells during the postnatal growth phase. We suggest

that BMPs maintain precursor proliferation to generate a sufficiently large precursor cell pool, and cells become quiescent once BMP signaling is withdrawn during muscle maturation.

The exact source and identity of BMPs that control postnatal satellite cell activity remain unknown. Here, we show the presence of BMP transcripts in satellite cells at different time points of postnatal development. However, the respective roles of the various BMPs synthesized by satellite cells and from other sources remain to be determined.

Abnormally high levels of BMP signaling in skeletal muscle can trigger ectopic bone formation, as seen in individuals suffering from fibrodysplasia ossificans progressiva (Shore et al., 2006). Interestingly, myogenic precursors contribute only minimally to BMP-mediated heterotopic ossification (<5%) *in vivo* (Lounev et al., 2009). Using AAV-mediated overexpression of *Bmp4*, we observed an important ossification of soft tissue in the hindlimbs of adult mice after 4 weeks of treatment (data not shown), which is similar to the effects previously reported in the literature (Lounev et al., 2009). Ectopic overexpression of BMP4 likely caused uncontrolled high ligand levels that initiated the osteogenic program in skeletal muscle.

Our results suggest that source, type of BMP ligands, presence of antagonists and expression of receptors must be tightly coordinated to allow correct muscle growth and homeostasis. It remains to be determined whether and how satellite cell-derived BMPs signal to neighboring cells and whether this defines the respective position of satellite cells within their niche. Future BMP gain-of-function experiments and ligand-specific knockout are required to elucidate the role of specific ligands. In conclusion, BMP signaling is an important regulatory pathway during postnatal muscle growth and determines satellite cell-dependent myofiber growth and the size of the adult muscle satellite cell pool.

MATERIALS AND METHODS

Animals

Rosa26-LoxP-Stop-LoxP-huSMAD6-IRES-EGFP transgenic mice (on a *C57BL/6J* background), also labeled *RS6*, were crossed with the different Cre-driver mice described below. The generation of this mouse line is described in the supplementary Materials and Methods. *Pax7^{CreERT2/+}* knock-in mice [JAX strain name is *B6;129-Pax7tm2.1(cre/ERT2)Fan/J*] were crossed with wild-type *C57BL/6J* mice. This strain expresses CRE-ERT2 recombinase from the endogenous *Pax7* locus (Lepper et al., 2009). By crossing *Pax7^{CreERT2/+}* with the *RS6* strain, we obtained *Pax7^{CreERT2/+}; RS6^{+/-}* offspring. Transgenic *HSA-Cre* mice [JAX strain name *FVB.Cg-Tg(ACTA1-cre)79Jme/J* on a *C57BL/6J* background] have the *Cre* recombinase gene driven by the human α -skeletal actin (*HSA*) promoter (Miniou et al., 1999). By crossing these mice with the *RS6* strain, we obtained *HSA-Cre^{+/-}; RS6^{+/-}* offspring. *Alk3^{fllox/fllox}* mice (JAX strain name is *Bmpr1a^{tm2.1Bhr}*) contain *LoxP* sites flanking exon 2 of *Alk3* (Mishina et al., 2002). By crossing *Alk3^{fllox/fllox}* with *Pax7^{CreERT2/+}; Alk3^{fllox/+}*, we obtained *Pax7^{CreERT2/+}; Alk3^{fllox/fllox}* offspring. The mice were bred in the animal facility of either the Medical Faculty of Paris VI or the Imagine Institute and were kept according to institutional guidelines. Wild-type *C57BL/6J* mice were purchased from Janvier or Charles River. Animal studies have been approved and were carried out under the laboratory and animal facility licenses.

AAV-injection

AAV quantity for intramuscular delivery was calculated relative to total body weight [$x(\text{in } \mu\text{l})=1.5 \times \text{body weight (in g)}$], which was between 5 and 30 μl . AAV was injected into the triceps brachii muscle or into the muscles of the anterior compartment of the lower leg of 3-day-old *C57BL/6J* mice. Control muscles were either non-injected or injected with PBS as stated in the text and legends. As in previous work, we never observed any effect on muscle morphology or histology in control injected animals when injecting PBS intramuscularly with the exception of some regenerating fibers along the injection trajectory (Sartori et al., 2013). AAV-*Nog* was used at a concentration of 1×10^{13} viral genomes (vg)/ml. The plasmid construction and AAV production procedures are described in the supplementary Materials and Methods. At 4 weeks of age, muscles were isolated and prepared for cryosections/histology, qPCR or isolation of single muscle fibers.

Tamoxifen injection for induction of Cre-ERT2 activity

Tamoxifen (Sigma) was prepared in heated corn oil (Sigma) at 37°C at 20 mg/ml and 2.5 $\mu\text{l/g}$ were administered by intra-peritoneal injection into pups (P7 and P9), which were sacrificed at the ages of 1 or 2 months. Adult

mice (for primary myoblast cultures, see below), between 2 and 4 months of age, were injected with 100 μl daily for 5 days, and were sacrificed 1 week after the first injection.

FACS isolation and culture of satellite cells

For fluorescent-activated cell sorting, muscles (forelimb, hindlimb, abdominal, pectoral) were processed from P3, P14, P21 and P28 mice. The dissection of the muscles was performed with care to take off as much fat and connective tissue as possible. The muscles were minced in Hank's Balanced Salt Solution (HBSS) supplemented with 0.2% bovine serum albumin, 1% penicillin-streptomycin in a sterile 6 cm Petri dish on ice. The minced muscles were digested for 1.5 h at 37°C with 2 $\mu\text{g/ml}$ collagenase A (Roche), 2.4 U/ml dispase I (Roche), 10 ng/ml DNase I (Roche), 0.4 mM CaCl_2 and 5 mM MgCl_2 in supplemented HBSS. Cells were washed with supplemented HBSS, filtered through a 100 μm cell strainer and pelleted. The washing step was repeated with 70 μm and finally 40 μm cell strainers.

For labeling extracellular markers, the following primary antibodies were used (10 ng/ml): rat anti-mouse CD45-PE-Cy7 (BD), rat anti-mouse Ter119-PE-Cy7 (BD), rat anti-mouse CD34-BV421 (BD), rat anti-mouse integrin- α 7-A700 (R&D Systems) and rat anti-mouse Sca1-FITC (BD). Cells were washed once with ice-cold supplemented HBSS, filtered and resuspended in supplemented HBSS. Flow cytometric analysis and cell sorting were performed on a FACSAriaII (BD) previously calibrated (Fluorescence Minus One and use of compensation beads) using the Lumic-CyPS UPMC platform. TER119 (LY76)⁺ and CD45 (PTPRC, LY5)⁺ cells were negatively selected, CD34⁺ and integrin- α 7⁺ cells were positively selected and the remaining cells were gated based on SCA1⁻ expression. The selected cells were collected in a FACS tube containing lysis buffer and were directly processed for RNA extraction as described below.

Culture of satellite cell-derived primary myoblasts using the pre-plating method

Cells from adult muscle tissue, prepared in a similar way to the method used for the FACS purification procedure, were resuspended in growth medium (see FACS procedure) and pre-plated onto a non-coated 15 cm Petri dish for 4 h (fibroblasts will adhere to the plate, whereas most myoblasts will remain in suspension). The media contained myoblasts in suspension and was transferred onto gelatin-coated 10 cm Petri dishes. Cultures were maintained in growth medium until cells reached 70% confluency, after which cells were harvested by trypsinization for RNA extraction.

MACS isolation and culture of satellite cells

Satellite cells were isolated from forelimb, hindlimb and back muscles of 6- to 8-week-old female *C57BL/6* mice using the skeletal muscle dissociation kit (Miltenyi Biotec, 130-098-305) followed by magnetic-activated cell sorting (MACS). MACS separation involved an initial enrichment step using the mouse satellite cell isolation kit (Miltenyi Biotec, 130-104-268) followed by further purification with mouse anti-integrin α -7 microbeads (Miltenyi Biotec, 130-104-261). Isolated cells were plated on growth factor reduced matrigel (Corning)-coated dishes in medium containing DMEM (Gibco), 15% FBS (Gibco), 2.5 ng/ml basic FGF (Sigma), 10 ng/ml leukemia inhibitory factor (BioChrom) and 1% Pen/Strep (Gibco), and maintained in a humidified hypoxic 3% O_2 /5% CO_2 atmosphere at 37°C. After the first 24 h in culture, $1 \times \text{B27}$ without vitamin A (Gibco) was added to the medium. Following a 2-day culture period, which permitted sufficient expansion of the satellite cells without loss of Pax7 positivity, cells were treated with 100 ng/ml recombinant human BMP4 (R&D Systems, 314-BP) or with the vehicle used to reconstitute BMP4 (4 mM HCl containing 0.1% bovine serum albumin) in a serum-free medium. Prior to incubation with BMP4, cells were switched to a serum-free medium for 6 h to eliminate the effect from unknown BMP signaling components in the serum. Where specified, BMP soluble receptor (recombinant mouse BMPRII-IA/ALK3-Fc Chimera, R&D Systems, 437-MR) in a concentration of 200 ng/ml was added to the medium to block residual BMP signaling components. Following cell harvest, cells were immediately lysed and total RNA was extracted using the RNeasy Micro kit (Qiagen). Reverse transcription was performed using SuperScript III Reverse Transcriptase (Invitrogen).

Quantitative real-time PCR (RT-qPCR) was performed on the 7000 Sequence Detection System (Applied Biosystems) using SYBR Green I detection chemistry (Applied Biosystems).

RNA isolation and real-time PCR

Total RNA from frozen muscle tissue was isolated using Trizol (Invitrogen) extraction in combination with RNeasy Mini kit (Qiagen). Total RNA from FACS-isolated satellite cells was isolated using the RNAqueous Microkit (Ambion kit, Life Technologies). Total RNA from cultured primary myoblasts was isolated using the RNeasy Micro kit (Qiagen). In all cases, RNase-Free DNase I Set (Qiagen or Life Technologies) was used to eliminate traces of DNA in the RNA extract. Isolated RNA was quantified using NanoVue Plus GE HealthCare spectrophotometer (Dutscher). For RNA extracted from muscle tissue and from cultured myoblasts, cDNA synthesis was performed using the ThermoScript RT-PCR system (Invitrogen) with random hexamer primers for first-strand cDNA synthesis. For RNA extracted from FACS-isolated satellite cells, cDNA synthesis was performed using SuperScript VILO Master Mix (Invitrogen). Real-time polymerase chain reaction (RT-qPCR) was performed according to the SYBR Green protocol (BioRad) in triplicate on the CFX96 Touch Real-Time detection system (BioRad) using iTaq Universal SYBR Green Supermix (BioRad). Alternatively, reverse transcription was performed using SuperScript III Reverse Transcriptase (Invitrogen), followed by RT-qPCR on the 7000 Sequence Detection System (Applied Biosystems) using SYBR Green I detection chemistry (Applied Biosystems). A 10 min denaturation step at 94°C was followed by 40 cycles of denaturation at 94°C for 10 s and annealing/extension at 60°C for 30 s. Before sample analysis, we had determined for each gene and primer set the PCR efficiencies with a standard dilution series (10E1-10E7 copies/μl), which subsequently enabled us to determine the copy numbers from the C_t values. mRNA levels were normalized to 10E3 or 10E6 copies of *Gapdh* mRNA. Fold changes were calculated according to the efficiency corrected $-\Delta\Delta C_t$ method (Pfaffl, 2001). The sequences for the primers used are listed in Table S1.

Immunocytochemistry/immunohistochemistry

Immunocytochemistry/histological analyses were performed using primary antibodies against Pax7 (1/50 mouse IgG1 from DSHB or alternatively 1/2 mouse IgG1 DSHB-hybridoma cell supernatant), pSmad1/5 (1/50, rabbit, Cell Signaling, 9516), laminin (1/400, rabbit, Dako, Z0097), anti-BrdU (1/100, rat, Abcam, ab6326), m-Cadherin (1/50, mouse IgG1, Nanotools, 0106-100), MyoD (1/100, rabbit IgG1, Santa Cruz Biotechnology, sc760), myogenin (1/100, mouse IgG1, DSHB), panMHC (mouse Ig2a, A4-1025, DSHB), Ki67 (1/100, mouse IgG1, BD Biosciences, 556003) and cleaved-caspase 3 (1/300, Cell Signaling, 9664), followed by secondary antibodies with various fluorophores (Alexa Fluor 1/400 goat anti-mouse IgG1 488 or 594, goat anti-rabbit 488 or 594) and DAPI (1/1000 or 1/5000, Sigma). Fluorescence was visualized using a Zeiss Axio Imager with an Orkan camera (Hamamatsu) and AxioVision software.

Fluorescence intensity quantification

All parameters during image acquisition were kept the same. Fluorescence intensity was quantified using ImageJ software. The background was removed and the regions of interest (ROIs; in this case nuclei) were identified using the software 'Nucleus Counter' plug-in. 'Integrated Density' and 'Area' measurements were performed for each nucleus and the corrected fluorescence intensity was calculated as follows: corrected fluorescence intensity=integrated density÷area.

BrdU analysis

Mice were treated with AAV-*Nog* or AAV-control, which were intramuscularly injected into the tibialis anterior (TA) muscle at P3. At P14, animals were labeled with BrdU (Invitrogen) by subcutaneous injection with 10 μl per 1 g body weight for 3 consecutive days. Following sacrifice, histological sections of the TA muscle (12 μm) were fixed with 4% paraformaldehyde for 10 min and permeabilized with methanol (−20°C) for 6 min. Antigens were retrieved by boiling for 30 min at 70–80°C in 0.01 M sodium nitrate (pH 6). This was followed by incubation with HCl (1 N) for 20 min at 37°C. Samples were washed in PBS

and incubated for 1 h in blocking buffer (2% BSA and 2% porcine serum). Samples were incubated overnight at 4°C with anti-BrdU (rat, Abcam) in combination with other primary antibodies (see above).

Western blot

Proteins were extracted from frozen triceps brachii muscle using RIPA buffer with a proteinase and phosphatase inhibitor cocktail (Complete tablets, Roche). Proteins were separated through denaturing SDS-polyacrylamide gel electrophoresis with the Laemmli system and transferred onto nitrocellulose membranes using the wet method (BioRad). The blots were probed using primary antibodies against GFP (1/5000, Aves Labs) and Actin (1/10000, Sigma). Western blots were analyzed with SuperSignal West Pico Chemiluminescent substrate (Pierce).

Single fiber preparation

Mice were sacrificed at P3 and P28. TA and extensor digitorum longus (EDL) muscles were surgically isolated. Muscles were thereafter digested in 0.2% collagenase type I dissolved in DMEM (Life Technologies). Individual, viable, undamaged myofibers were isolated by gently passing them through Pasteur pipettes with different sized apertures as described in detail elsewhere (Moyle and Zammit, 2014). Then the myofibers were fixed in 4% paraformaldehyde dissolved in PBS (Sigma) for 10 min, washed, stained against Pax7 (1/50, mouse IgG1, DSHB) and with DAPI, and mounted on slides.

Morphometric studies

Cryosections of 12 μm of TA muscles were stained with anti-laminin to delineate the muscle fibers and anti-Pax7 or anti-m-Cadherin to label satellite cells. Fluorescent photographs were taken with a ×20 objective on a microscope (Zeiss, AxioImage) and saved as TIFF files. These images were projected onto a flatscreen coupled with a graphic tablet, which enabled the manual retracing of the muscle fiber outlines and the counting of satellite cells. The fibers of the entire muscle cross-section were analyzed.

For myonuclear domain analysis, single fibers were stained with Pax7 and DAPI. Images of at least three different segments of each fiber were acquired with a ×40 objective on a microscope (Zeiss, AxioImage) and the number of Pax7⁺ nuclei was quantified. The volume of each fiber segment was then assessed on the acquired images by measuring with ImageJ software the length (L) of the fiber segment and the fiber diameter (D) as follows: volume=π×(D÷2)²×L. The myonuclear domain was then calculated as follows: myonuclear domain=volume÷number of nuclei.

Statistical analysis

The results are expressed as the mean together with the standard error of the mean (s.e.m.) for qPCR data. Other data are presented as dot plots of the median or as Whiskers-Tukey box plots. The probability for statistical differences between two experimental groups was determined through calculation of the *P* value using the two-tailed unpaired *t*-test.

Acknowledgements

We thank Dr Yuji Mishina (University of Michigan, Ann Arbor, MI, USA) for providing the *Alk3^{fl/fl}* mice.

Competing interests

The authors declare no competing or financial interests.

Author contributions

Conceptualization: F.L.G., L.G., C. Birchmeier, T.B., M.S., F.R., H.A.; Methodology: S.S., S.A.-M., T.B.; Validation: A.S., E.S., S.S., T.B., M.S., F.R., H.A.; Formal analysis: A.S., E.S., I.P., F.Z.; Investigation: A.S., E.S., S.A.-M., I.P., F.Z., E.M.; Resources: S.S., C. Beley, A.J., C.C., T.B.; Writing - original draft: A.S., E.S., M.S., H.A.; Writing - review & editing: A.S., E.S., S.S., S.A.-M., I.P., E.M., F.L.G., C. Birchmeier, T.B., M.S., H.A.; Visualization: A.S., E.S., M.S., H.A.; Supervision: C. Birchmeier, T.B., M.S., F.R., H.A.; Project administration: C. Birchmeier, T.B., M.S., F.R., H.A.; Funding acquisition: A.S., E.S., C. Birchmeier, T.B., M.S., F.R., H.A.

Funding

This work was supported by the Association Française contre les Myopathies (AFM) to E.M., C. Beley, L.G., F.R. and H.A.; by the Agence Nationale de la Recherche (ANR) to F.R. and H.A. (ANR-12-BSV10038, ANR-16-CE14-0002-01), and to C.C.

and F.R. (ANR-13-BSV1-0011); by the National Institutes of Health-National Institute of Arthritis and Musculoskeletal and Skin Diseases to C.C. (R01 AR057344); by the Deutsche Forschungsgemeinschaft (DFG) to A.S., M.S. and C. Birchmeier (as part of the MyoGrad International Graduate School for Myology, GK 1631/1); by the Fondation pour la Recherche Médicale (FRM) to A.S. (FDT20140930879); by the Ministère de l'Enseignement Supérieur et de la Recherche to E.S. and A.J.; and by the Université Franco-allemande (UFA, as part of the MyoGrad International Graduate School for Myology, CDFA-06-11) to E.S., A.S., I.P., F.R., H.A., C. Birchmeier, L.G. and M.S. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Deposited in PMC for release after 12 months.

Supplementary information

Supplementary information available online at
<http://dev.biologists.org/lookup/doi/10.1242/dev.144089.supplemental>

References

- Amthor, H., Christ, B., Weil, M. and Patel, K.** (1998). The importance of timing differentiation during limb muscle development. *Curr. Biol.* **8**, 642-652.
- Amthor, H., Christ, B. and Patel, K.** (1999). A molecular mechanism enabling continuous embryonic muscle growth - a balance between proliferation and differentiation. *Development* **126**, 1041-1053.
- Amthor, H., Christ, B., Rashid-Doubell, F., Kemp, C. F., Lang, E. and Patel, K.** (2002). Follistatin regulates bone morphogenetic protein-7 (BMP-7) activity to stimulate embryonic muscle growth. *Dev. Biol.* **243**, 115-127.
- Beilharz, M. W., Lareu, R. R., Garrett, K. L., Grounds, M. D. and Fletcher, S.** (1992). Quantitation of muscle precursor cell activity in skeletal muscle by Northern analysis of MyoD and myogenin expression: application to dystrophic (mdx) mouse muscle. *Mol. Cell. Neurosci.* **3**, 326-331.
- Clever, J. L., Sakai, Y., Wang, R. A. and Schneider, D. B.** (2010). Inefficient skeletal muscle repair in inhibitor of differentiation knockout mice suggests a crucial role for BMP signaling during adult muscle regeneration. *Am. J. Physiol. Cell Physiol.* **298**, C1087-C1099.
- Fukada, S.-i., Yamaguchi, M., Kokubo, H., Ogawa, R., Uezumi, A., Yoneda, T., Matev, M. M., Motohashi, N., Ito, T., Zolkiewska, A. et al.** (2011). Hes1 and Hes3 are essential to generate undifferentiated quiescent satellite cells and to maintain satellite cell numbers. *Development* **138**, 4609-4619.
- Goto, K., Kamiya, Y., Imamura, T., Miyazono, K. and Miyazawa, K.** (2007). Selective inhibitory effects of Smad6 on bone morphogenetic protein type I receptors. *J. Biol. Chem.* **282**, 20603-20611.
- Hirsinger, E., Duprez, D., Jouve, C., Malapert, P., Cooke, J. and Pourquie, O.** (1997). Noggin acts downstream of Wnt and Sonic Hedgehog to antagonize BMP4 in avian somite patterning. *Development* **124**, 4605-4614.
- Huang, P., Schulz, T. J., Beauvais, A., Tseng, Y.-H. and Gussoni, E.** (2014). Intramuscular adipogenesis is inhibited by myo-endothelial progenitors with functioning Bmpr1a signalling. *Nat. Commun.* **5**, 4063.
- Irshad, S., Bansal, M., Guarnieri, P., Davis, H., Al Haj Zen, A., Baran, B., Pinna, C. M. A., Rahman, H., Biswas, S., Bardella, C. et al.** (2017). Bone morphogenetic protein and Notch signalling crosstalk in poor-prognosis, mesenchymal-subtype colorectal cancer. *J. Pathol.* **242**, 178-192.
- Jen, Y., Weintraub, H. and Benezra, R.** (1992). Overexpression of Id protein inhibits the muscle differentiation program: in vivo association of Id with E2A proteins. *Genes Dev.* **6**, 1466-1479.
- Krause, C., Guzman, A. and Knaus, P.** (2011). Noggin. *Int. J. Biochem. Cell Biol.* **43**, 478-481.
- Lepper, C., Conway, S. J. and Fan, C.-M.** (2009). Adult satellite cells and embryonic muscle progenitors have distinct genetic requirements. *Nature* **460**, 627-631.
- Lounev, V. Y., Ramachandran, R., Wosczyzna, M. N., Yamamoto, M., Maidment, A. D. A., Shore, E. M., Glaser, D. L., Goldhamer, D. J. and Kaplan, F. S.** (2009). Identification of progenitor cells that contribute to heterotopic skeletogenesis. *J. Bone Joint Surg.* **91**, 652-663.
- Matsumoto, A., Takeishi, S., Kanie, T., Susaki, E., Onoyama, I., Tateishi, Y., Nakayama, K. and Nakayama, K. I.** (2011). p57 is required for quiescence and maintenance of adult hematopoietic stem cells. *Cell Stem Cell* **9**, 262-271.
- Mauro, A.** (1961). Satellite cell of skeletal muscle fibers. *J. Biophys. Biochem. Cytol.* **9**, 493-495.
- Miniou, P., Tiziano, D., Frugier, T., Roblot, N., Meur, M. L. and Melki, J.** (1999). Gene targeting restricted to mouse striated muscle lineage. *Nucl. Acids Res.* **27**, e27-e30.
- Mishina, Y., Hanks, M. C., Miura, S., Tallquist, M. D. and Behringer, R. R.** (2002). Generation of Bmpr/Alk3 conditional knockout mice. *Genesis* **32**, 69-72.
- Miyazono, K. and Miyazawa, K.** (2002). Id: a target of BMP signaling. *Sci. STKE* **2002**, pe40.
- Moyle, L. A. and Zammit, P. S.** (2014). Isolation, culture and immunostaining of skeletal muscle fibres to study myogenic progression in satellite cells. *Methods Mol. Biol.* **1210**, 63-78.
- Nohe, A., Hassel, S., Ehrlich, M., Neubauer, F., Sebald, W., Henis, Y. I. and Knaus, P.** (2002). The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. *J. Biol. Chem.* **277**, 5330-5338.
- Nohe, A., Keating, E., Knaus, P. and Petersen, N. O.** (2004). Signal transduction of bone morphogenetic protein receptors. *Cell. Signal.* **16**, 291-299.
- Ono, Y., Calhabeu, F., Morgan, J. E., Katagiri, T., Amthor, H. and Zammit, P. S.** (2011). BMP signalling permits population expansion by preventing premature myogenic differentiation in muscle satellite cells. *Cell Death Differ.* **18**, 222-234.
- Pfaffl, M. W.** (2001). A new mathematical model for relative quantification in real-time RT-PCR. *Nucl. Acids Res.* **29**, e45.
- Pourquie, O., Fan, C.-M., Coltey, M., Hirsinger, E., Watanabe, Y., Bréant, C., Francis-West, P., Brickell, P., Tessier-Lavigne, M. and Le Douarin, N. M.** (1996). Lateral and axial signals involved in avian somite patterning: a role for BMP4. *Cell* **84**, 461-471.
- Relaix, F. and Marcelle, C.** (2009). Muscle stem cells. *Curr. Opin. Cell Biol.* **21**, 748-753.
- Sartori, R., Schirwis, E., Blaauw, B., Bortolanza, S., Zhao, J., Enzo, E., Stantzou, A., Mouisel, E., Toniolo, L., Ferry, A. et al.** (2013). BMP signaling controls muscle mass. *Nat. Genet.* **45**, 1309-1318.
- Shore, E. M., Xu, M., Feldman, G. J., Fenstermacher, D. A., Cho, T.-J., Choi, I. H., Connor, J. M., Delai, P., Glaser, D. L., LeMerrer, M. et al.** (2006). A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. *Nat. Genet.* **38**, 525-527.
- Tylzanowski, P., Mebis, L. and Luyten, F. P.** (2006). The Noggin null mouse phenotype is strain dependent and haploinsufficiency leads to skeletal defects. *Dev. Dyn.* **235**, 1599-1607.
- Wang, H., Noulet, F., Edom-Vovard, F., Le Grand, F. and Duprez, D.** (2010). Bmp signaling at the tips of skeletal muscles regulates the number of fetal muscle progenitors and satellite cells during development. *Dev. Cell* **18**, 643-654.
- White, R. B., Biérinx, A.-S., Gnocchi, V. F. and Zammit, P. S.** (2010). Dynamics of muscle fibre growth during postnatal mouse development. *BMC Dev. Biol.* **10**, 21.
- Zalc, A., Hayashi, S., Auradé, F., Bröhl, D., Chang, T., Mademtoglou, D., Mourikis, P., Yao, Z., Cao, Y., Birchmeier, C. et al.** (2014). Antagonistic regulation of p57kip2 by Hes/Hey downstream of Notch signaling and muscle regulatory factors regulates skeletal muscle growth arrest. *Development* **141**, 2780-2790.